Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.
Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, Graham J, Kato T, Ruffinelli JC, André T, Carrière Roussel E, Klauck I, Groc M, Vedovato JC, Tabernero J. Van Cutsem E, et al. Among authors: yaeger r. J Clin Oncol. 2023 May 10;41(14):2628-2637. doi: 10.1200/JCO.22.01693. Epub 2023 Feb 10. J Clin Oncol. 2023. PMID: 36763936 Free PMC article. Clinical Trial.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. Nissan MH, et al. Among authors: yaeger r. Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27. Cancer Res. 2014. PMID: 24576830 Free PMC article.
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F. Francis JH, et al. Among authors: yaeger r. Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017 Jul 12. Ophthalmology. 2017. PMID: 28709702 Free PMC article.
KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver.
Popovic M, Talarico O, van den Hoff J, Kunin H, Zhang Z, Lafontaine D, Dogan S, Leung J, Kaye E, Czmielewski C, Mayerhoefer ME, Zanzonico P, Yaeger R, Schöder H, Humm JL, Solomon SB, Sofocleous CT, Kirov AS. Popovic M, et al. Among authors: yaeger r. EJNMMI Res. 2020 Nov 23;10(1):142. doi: 10.1186/s13550-020-00707-0. EJNMMI Res. 2020. PMID: 33226505 Free PMC article.
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.
Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. Gao Y, et al. Among authors: yaeger r. Cancer Discov. 2018 May;8(5):648-661. doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26. Cancer Discov. 2018. PMID: 29483135 Free PMC article.
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.
van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. van Geel RMJM, et al. Among authors: yaeger r. Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31. Cancer Discov. 2017. PMID: 28363909 Free PMC article. Clinical Trial.
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Corcoran RB, et al. Among authors: yaeger r. Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431699 Free PMC article. Clinical Trial.
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Van Cutsem E, et al. Among authors: yaeger r. J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892987 Free PMC article. Clinical Trial.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Kopetz S, et al. Among authors: yaeger r. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566309 Clinical Trial.
176 results